Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Vilazodone in Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, 18-70 years of age.~* Currently meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for Major Depressive Disorder.~* The patient's current major depressive episode must be at least 8 weeks and no longer than 12 months in duration.~Exclusion Criteria:~* Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control.~* Patients with a history of meeting DSM-IV-TR criteria for:~  * Any manic, hypomanic or mixed episode, including bipolar disorder and substance-induced manic, hypomanic, or mixed episode~ * Any depressive episode with psychotic or catatonic features~ * Panic disorder with or without agoraphobia~ * Obsessive-compulsive disorder~ * Schizophrenia, schizoaffective, or other psychotic disorder~ * Bulimia or anorexia nervosa~ * Presence of borderline personality disorder or antisocial personality disorder~ * Mental retardation, dementia, amnesia, or other cognitive disorders.~* Patients who are considered a suicide risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received 2 placebo to vilazodone tablets, and 1 placebo to citalopram capsule orally once daily for the 11 weeks of the study.
- Vilazodone 20 mg/day (Type: EXPERIMENTAL): Participants received 1 vilazodone tablet, 1 placebo to vilazodone tablet, and 1 placebo to citalopram capsule orally once daily for the 11 weeks of the study. Participants received vilazodone 10 mg/day during Week 1, vilazodone 20 mg/day during Weeks 2 to 10, and vilazodone 10 mg/day during Week 11.
- Vilazodone 40 mg/day (Type: EXPERIMENTAL): Participants received 1 placebo to vilazodone tablet, 1 vilazodone tablet, and 1 placebo to citalopram capsule orally once daily during Weeks 1 and 2 of the study. Participants received 2 vilazodone tablets and 1 placebo to citalopram capsule orally once daily during Weeks 3 -10 of the study. Participants received vilazodone 10 mg/day during Week 1, vilazodone 20/day mg during Week 2, and vilazodone 40 mg/day during Weeks 3 to 10. During Week 11, participants received vilazodone 20 mg/day for 4 days and 10 mg/day for 3 days.
- Citalopram 40 mg/day (Type: ACTIVE_COMPARATOR): Participants received 2 placebo vilazodone tablets, and 1 citalopram capsule once daily for the 11 weeks of the study. Participants received citalopram 20 mg/day during Weeks 1 and 2, citalopram 40 mg/day during Weeks 3 to 10, and citalopram 20 mg/day during Week 11.

Based on this trial design, predict the completion outcome and termination type (if applicable).